Results 71 to 80 of about 126,889 (304)

Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy. [PDF]

open access: yes, 2014
Osteosarcoma, the most common primary bone sarcoma, is a genetically complex disease with no widely accepted biomarker to allow stratification of patients for treatment.
M. Fernanda Amary   +44 more
core   +1 more source

One size does not fit all: An in vitro evaluation of the effects of bezafibrate and medroxyprogesterone acetate on human SH‐SY5Y and U‐87 MG cancer cells

open access: yesFEBS Open Bio, EarlyView.
Drugs previously repurposed to target blood cancers reduced neuroblastoma and glioblastoma cell growth and viability. However, their levels of anticancer activity were different and their clinical application may be problematic due to side effects at effective doses.
Abhishek Kharawatkar   +4 more
wiley   +1 more source

PiRNA hsa_pir_018849 promotes the proliferation and invasion of osteosarcoma cells by regulating the stability of CCN5 mRNA

open access: yesJournal of Orthopaedic Surgery and Research
Background Osteosarcoma is a primary malignant bone tumor and that is predominantly found in adolescents and young adults, and it often occurs during periods of rapid bone growth.
Jiale Huang   +5 more
doaj   +1 more source

Dog breeds and body conformations with predisposition to osteosarcoma in the UK: a case-control study

open access: yesCanine Medicine and Genetics, 2021
Background Osteosarcoma is an aggressive and painful bone neoplasm in dogs. Previous studies have reported epidemiological associations suggesting that large body mass, long bone length and the genetics of certain breeds including the Rottweiler are ...
Grace L. Edmunds   +7 more
doaj   +1 more source

"The Treatment of Localized Osteosarcoma of the Extremity: the Italian Experience (Studies of the National Council of Research)" [PDF]

open access: yes, 1991
"The Treatment of Localized Osteosarcoma of the Extremity: the Italian Experience (Studies of the National Council of Research)
M. CAMPANACCI   +8 more
core  

UiO‐66 metal–organic frameworks in biomedicine: From structural tunability to bioimaging, photodiagnostics, and photodynamic cancer therapy

open access: yesFEBS Open Bio, EarlyView.
UiO‐66(Zr) metal–organic frameworks are chemically stable, biocompatible, and highly tunable nanomaterials. Their modular structure enables controlled drug delivery, multimodal bioimaging, and light‐activated photodynamic therapy, supporting integrated diagnostic and therapeutic (theranostic) applications in cancer and biomedical research.
Veronika Huntošová   +2 more
wiley   +1 more source

The role of eukaryotic initiation factor 4E (eIF4E) in osteosarcoma metastasis [PDF]

open access: yes, 2011
The most significant problem for cancer patients is the dissemination of cancer cells and the formation of metastatic disease. Emblematic of the problem is the clinical progression seen in most patients with osteosarcoma, where metastasis to the lung is ...
Osborne, Tanasa S.
core  

From energy provision to protein synthesis: Tunnelling nanotubes as mediators of intercellular metabolic cooperation in cancer

open access: yesFEBS Open Bio, EarlyView.
The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley   +1 more source

Triptolide inhibits the growth of osteosarcoma by regulating microRNA-181a via targeting PTEN gene in vivo and vitro

open access: yesTumor Biology, 2017
We aimed to study the anti-tumor effects of triptolide on osteosarcoma and the related molecular mechanisms. The cell viability, apoptosis portion, tumor size, tumor weight, and invasion of osteosarcoma cells were determined.
Chunming Jiang   +8 more
doaj   +1 more source

Suppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1. [PDF]

open access: yesPLoS ONE, 2011
BACKGROUND: The cellular and molecular mechanisms of tumour response following chemotherapy are largely unknown. We found that low dose anti-tumour agents up-regulate early growth response 1 (EGR1) expression. EGR1 is a member of the immediate-early gene
Yukihiro Matsunoshita   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy